Literature DB >> 10322098

Multidrug-resistant tuberculosis in Alberta and British Columbia, 1989 to 1998.

A Hersi1, K Elwood, R Cowie, D Kunimoto, R Long.   

Abstract

OBJECTIVE: To describe the extent of the problem of multidrug-resistant tuberculosis (MDR-TB) in Alberta and British Columbia from 1989 to 1998.
DESIGN: A retrospective, population-based descriptive study of all notified MDR-TB cases in the context of all notified TB cases, all notified culture-positive TB cases and all notified drug-resistant TB cases.
SETTING: Provinces of Alberta and British Columbia, and their TB registries. PATIENTS: All people with TB reported to the TB registries of Alberta and British Columbia between January 1, 1989 and June 30, 1998. MAIN OUTCOME MEASURES: Drug susceptibility testing was performed in all cases of culture-positive TB. Demographic, clinical and laboratory data on all cases of MDR-TB were recorded.
RESULTS: Of 4606 notified cases of TB, 3553 (77.1%) were culture positive. Of these, 365 (10.3%) were drug resistant; of the drug-resistant cases, 24 (6.6%) were MDR. Most MDR-TB patients were foreign-born; of the four Canadian-born patients, two were infected while travelling abroad. Although foreign-born patients were significantly more likely to harbour drug-resistant strains, 14.3% versus 4.8%, respectively (P<0.001), among those who were harbouring a drug-resistant strain, the proportion of Canadian-born versus foreign-born patients with an MDR strain was the same (6.7% versus 6. 6%, respectively). From 1994 to 1998 versus 1989 to 1993, the proportion of all drug-resistant strains that were MDR was greater (9.0% versus 4.3%, respectively), but the difference was not statistically significant. Isolates from 16 of the 24 MDR-TB cases had been archived. Each of these was fingerprinted and found to be unique. Most MDR-TB cases (88%) were respiratory. Of those tested for human immunodeficiency virus (n=17), only one was seropositive. MDR-TB was 'acquired' in 67% and 'primary' in 33% of cases. Eight (33%) of the MDR-TB cases received curative courses of treatment, six (25%) are still being treated, and the remainder have either died (five, 21%), transferred out (four, 17%) or become 'chronic' (one, 4%). No secondary case of MDR-TB has been identified in Alberta and British Columbia.
CONCLUSIONS: Most MDR-TB in Alberta and British Columbia is imported. The proportion of all drug-resistant cases that are MDR appears to be increasing, but not because of disease acquired from recent contact with MDR-TB in Canada.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10322098     DOI: 10.1155/1999/456395

Source DB:  PubMed          Journal:  Can Respir J        ISSN: 1198-2241            Impact factor:   2.409


  10 in total

Review 1.  Drug-resistant tuberculosis.

Authors:  R Long
Journal:  CMAJ       Date:  2000-08-22       Impact factor: 8.262

2.  Tuberculosis drug resistance in Canada, 1998 to 2000.

Authors:  M D Phypers; L Panaro; P Nault
Journal:  Can J Infect Dis       Date:  2001-05

3.  Drug resistance study of Mycobacterium tuberculosis in Canada, February 1, 1993 to January 31, 1994.

Authors:  E Farzad; D Holton; R Long; M FitzGerald; A Laszlo; H Njoo; A Fanning; E Hershfield; V Hoeppner; E Allen
Journal:  Can J Public Health       Date:  2000 Sep-Oct

Review 4.  Dimensions of poverty as risk factors for antimicrobial resistant organisms in Canada: a structured narrative review.

Authors:  Teagan King; Richelle Schindler; Swati Chavda; John Conly
Journal:  Antimicrob Resist Infect Control       Date:  2022-01-24       Impact factor: 4.887

5.  Multidrug-resistant tuberculosis: Treatment and outcomes of 93 patients.

Authors:  Sarah K Brode; Robert Varadi; Jane McNamee; Nina Malek; Sharon Stewart; Frances B Jamieson; Monica Avendano
Journal:  Can Respir J       Date:  2014-12-10       Impact factor: 2.409

6.  Active tuberculosis among homeless persons, Toronto, Ontario, Canada, 1998-2007.

Authors:  Kamran Khan; Elizabeth Rea; Cameron McDermaid; Rebecca Stuart; Catharine Chambers; Jun Wang; Angie Chan; Michael Gardam; Frances Jamieson; Jae Yang; Stephen W Hwang
Journal:  Emerg Infect Dis       Date:  2011-03       Impact factor: 6.883

7.  Drug-resistant tuberculosis in a tertiary referral teaching hospital of Korea.

Authors:  J H Lee; J H Chang
Journal:  Korean J Intern Med       Date:  2001-09       Impact factor: 2.884

8.  Rifampin-resistant/multidrug-resistant Tuberculosis in Alberta, Canada: Epidemiology and treatment outcomes in a low-incidence setting.

Authors:  Brett D Edwards; Jenny Edwards; Ryan Cooper; Dennis Kunimoto; Ranjani Somayaji; Dina Fisher
Journal:  PLoS One       Date:  2021-02-16       Impact factor: 3.240

Review 9.  Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis.

Authors:  James C Johnston; Neal C Shahidi; Mohsen Sadatsafavi; J Mark Fitzgerald
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

10.  Multidrug and extensively drug-resistant tuberculosis in Canada 1997-2008: demographic and disease characteristics.

Authors:  Jessica Minion; Victor Gallant; Joyce Wolfe; Frances Jamieson; Richard Long
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.